新闻公告

题目: Human Pluripotent Stem Cell-Based Disease Modeling and Drug Discovery报告人：Dr. Shuibing ChenWeill Cornell Medical College邀请人：姚雪彪 教授时间： 2018.6.7（周四），下午14:30 地点：生命科学学院329B会议室报告人简介：Dr. Chen is a professor of Chemical Biology in the Department of Surgery and Biochemistry at Weill Cornell Medical College. She graduated from Tsinghua University with Bachelor and Master Degrees in Chemistry in 1999 and 2002, respectively. She then joined Dr. Peter G. Schultz’s Group and received her doctorate from Kellogg School of Science and Technology, The Scripps Research Institute in 2006. She conducted her postdoctoral research at Harvard University to study the directed differentiation of human embryonic stem cells (hESCs) toward the pancreatic lineage. From then on, she joined the facuty of Weill Cornell Medical College in 2011. ISSCR President Hans Clevers said “Dr. Chen has developed cutting-edge chemical approaches in many applications. She has become a key player in human disease modeling, and discovered the first drug capable of preventing and treating Zikavirus disease in organoids and mice, setting new standards for research in the future.” The major research interest in the Chen Lab is to manipulate stem cell fate using chemical and biological approaches and to generate functional tissues and organs that can be used for translational research. Their current focus is on human pluripotent stem cells (PSCs), including hESCs and induced pluripotent stem cells (iPSCs). Their long-term goal is to apply specific PSC-derived tissues or organs to patient for replacement therapy and to build up “disease in a dish” platforms for drug discovery. 报告摘要：Human pluripotent stem cells (hPSCs) provide unlimited starting material to generate differentiated cells that can be used to build a functional organ. Essential to this pursuit is an efficient way to differentiate hPSCs into specific types of mature cells. Cell-permeable small molecules that can modulate the function of specific proteins provide a convenient and efficient approach to controlling stem/progenitor cell fate. Our laboratory has an in house chemical library containing 6,000 chemicals, including kinase inhibitors, signaling pathway regulators, nature products and FDA-approved drugs, and protein library containing 400 growth factors. Using high content and high throughput screening approaches, we have identified a series of small molecules that control stem cell self-renewal, differentiation and reprogramming. In addition, we have identified small molecules that direct hPSC differentiation into certain cell types, including pancreatic endocrine cells, pancreatic ductal epithelial cells, cardiac SA nodal cells, trophoblast cells, and colonic organoids. Using hPSCs derived cells or organoids, we have established several in vitro and in vivo platforms to study the role of genetic factors and environmental factors in the progression of diabetes, pancreatic cancer, colorectal cancer, and virus infection.